Synonyms: BMS962212 | compound 55 [PMID: 29077405]
Compound class:
Synthetic organic
Comment: BMS-962212 is a reversible, direct, and highly selective small molecule inhibitor of the serine protease FXIa [2].
|
|
No information available. |
Summary of Clinical Use ![]() |
BMS-962212 has completed Phase 1 (NCT03197779) clinical evaluation in healthy subjects in which its tolerability, PK and PD profiles were determined as being supportive of further evaluation [1] |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03197779 | A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects | Phase 1 Interventional | Bristol-Myers Squibb |